Per 1 January 2021 Utrecht University (UU) has joined hDMT as a new partner. The representatives in the hDMT Consortium Assembly are Bart Spee and Tina Vermonden.
Utrecht University (UU) has an excellent research infrastructure in the area of human and animal measurement models, with strong expertise in pharmaceutical sciences, regenerative medicine, and Organ-on-Chip technology. The UU shares a multidisciplinary infrastructure and key technology platforms (e.g., organoids, biofabrication, EV, IPSC, gene-editing) and develops advanced and patient-specific disease models to translate relevant drug targets. The models are translated into novel regenerative therapies based on e.g., living cell-, organoid-, biomaterial- driven and biofabrication- technologies. Fundamental stem cell research integrated with emerging technologies are further used in applied research to bridge interventions to veterinary and human clinical care contributing to the TPI initiative.
UU has a large network of stakeholders including the world-leading Hubrecht Institute, the University Medical Center Utrecht and the Princess Maxima Center.
Notable strengths of Utrecht research include advanced brain organoids and brain-on-chip models as well as 3D-engineered human cardiomyocytes, articulating joint-on-chip models, and liver-, bone-, cartilage, kidney- and bile duct-on-chip technology. Organized within interdisciplinary research hubs such as the Utrecht Platform for Organoid Technology (UPORT) and the Utrecht Advanced In vitro Models (UAIM) hubs, Utrecht adds further value to the national research landscape.